We also demonstrated that endogenous Gal-1 in CD4+ (but mainly in CD8+ T cells) acts as a negative regulator of anti-tumor immunity, and concluded that prostate tumors require Gal-1 in lymphocytes to evade immune responses. The gene discussed is LGALS1; the disease is neoplasm.